Navigation Links
Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer
Date:12/9/2010

SANTA ROSA, Calif., Dec. 9, 2010 /PRNewswire/ -- Osseon Therapeutics, Inc. today named Mr. Gary Coughlen, CPA as the company's Chief Financial Officer, effective immediately.

Mr. Coughlen was most recently the Chief Financial Officer of PolyRemedy, Inc., a private-equity medical device company focused on wound care management. Prior to PolyRemedy, he served as the CFO of Refractec Inc., a manufacturer, and distributor of ophthalmic surgical devices to the global market. Coughlen started in 1999 at the founder's stage with three employees and served as Refractec's CFO through its growth to 75 employees.  

Earlier in his career, Coughlen served as CFO at Scieran Technologies, Inc and was a Vice President at Sierra Capital. He began his career in the public accounting at PricewaterhouseCoopers.

"I'm looking forward to the opportunities ahead for Osseon," said Coughlen. "We have an incredible pipeline of products, a solid distribution plan and we are well-positioned for growth."

"Gary brings outstanding expertise to Osseon," said John Stalcup, Ph.D., CEO and President. "He has a broad range of experience in senior financial management positions with medical device companies, and an extensive background in the equity and debt capital markets. We welcome him to our leadership team and look forward to his contributions to Osseon."

Coughlen is a graduate of University of Washington, where he earned a bachelor's degree in Business Administration and UC-Berkley where he completed his Masters in Business Administration.

About Osseon

Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease.  Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the lower portion of the thoracic and the entire lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them.  Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union.  For more information, visit our web site at www.osseon.com.

Osseon is a registered trademark of Osseon Therapeutics, Inc.

The names of actual companies and products mentioned herein may be the trademarks of their respective owners.


'/>"/>
SOURCE Osseon Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... company focused on tissue protection, repair and regeneration, ... Co., Ltd., received a positive response from the ... design for RGN-137 to treat epidermolysis bullosa ("EB"). ... incorporates Thymosin beta 4 ("Tß4") as the active ...
(Date:2/27/2017)... , February 27, 2017 A recent research ... medical marijuana market alone is expected to reach a value of ... along with 28 states have legalized marijuana for medical ... Florida , North Dakota , ... were approved to use the drug in medical applications such as ...
(Date:2/27/2017)... PETACH TIKVAH, Israel , Feb. 27, ... a leading developer of adult stem cell technologies for ... S. Almenoff , M.D., Ph.D., FACP, and Arturo ... Directors.  "Dr. Almenoff and Mr. Araya ... at an exciting time for our company," said ...
Breaking Medicine Technology:
(Date:2/27/2017)... , ... February 27, 2017 , ... ... transplantation therapy, is proud to announce a new informational post on robotic hair ... Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) can sound ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design Awards & ... International Social Design Awards. , The 7th A' Social Design Award is ... Institutions worldwide with realized projects and conceptual works. , The first phase of ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing a ... Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads based on ... IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the sales process ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide ... with a specific LRRK2 mutation, according to a study released today at the ... evidence of a link between pesticides and incidence of sporadic PD through occupational ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release ... show in Cannes (France), XO Private has initiated a second print-run of its lavish ... almost a metre across when open, weighs in at more than six kilos, retails ...
Breaking Medicine News(10 mins):